HCW Biologics (HCWB) Stock: Buy, Sell, or Hold?
HCWB - HCW Biologics Inc. Common Stock
$2.24
-0.19 (-7.82%)
▼
5d:
-21.95%
30d:
-28.78%
90d:
+69.7%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 17, 2026
0d
Get Alerted When HCWB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: HCWB is down 22.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: HCWB is down 22.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: HCWB is currently trading at $2.24, which is considered slightly low relative to its 30-day fair value range of $2.48 to $3.43.
Technical Outlook: Technically, HCWB is in a strong uptrend. Immediate support is located at $2.10, while resistance sits at $3.81. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $30.00 (+1239.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HCWB is in a strong uptrend. Immediate support is located at $2.10, while resistance sits at $3.81. Short-term momentum is weak, with the stock down 7.8% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $30.00 (+1239.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.48 -
$3.43
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.8%)
- BULLISH: Trading 1239.3% below Wall St target ($30.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.48 -
$3.43
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.10
Resistance Level
$3.81
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.85
Wall Street Target
$30.00
(+1239.3%)
Revenue Growth (YoY)
1969.7%
Profit Margin
-83.0%
Share & Embed Analysis
Last updated: September 13, 2026 5:12 AM ET
Data refreshes hourly during market hours. Next update: 6:12 AM
Data refreshes hourly during market hours. Next update: 6:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HCWB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
